Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envolimab + Fruquintinib + SOX in Gastric Cancer
NCT05914610Phase 3Not yet recruiting
- Sponsor
- Fujian Medical University
- Start
- Sep 2023
- Primary completion
- Jul 2025
- Modality
- Fragment-Derived Small Molecules, Orthosteric Ligands, Nanobodies (VHH)
01
Overview
A Phase 3 trial of envafolimab, fruquintinib in gastric cancer (GC), sponsored by Fujian Medical University. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
envafolimabfruquintinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05914610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914610.